GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:001049816 | Endometrium | AEH | proteasomal protein catabolic process | 108/2100 | 490/18723 | 2.73e-12 | 4.67e-10 | 108 |
GO:004316116 | Endometrium | AEH | proteasome-mediated ubiquitin-dependent protein catabolic process | 88/2100 | 412/18723 | 1.54e-09 | 1.36e-07 | 88 |
GO:00457877 | Endometrium | AEH | positive regulation of cell cycle | 56/2100 | 313/18723 | 2.73e-04 | 3.14e-03 | 56 |
GO:00002098 | Endometrium | AEH | protein polyubiquitination | 44/2100 | 236/18723 | 4.83e-04 | 4.97e-03 | 44 |
GO:00330446 | Endometrium | AEH | regulation of chromosome organization | 36/2100 | 187/18723 | 8.27e-04 | 7.73e-03 | 36 |
GO:00447726 | Endometrium | AEH | mitotic cell cycle phase transition | 67/2100 | 424/18723 | 2.37e-03 | 1.78e-02 | 67 |
GO:00900686 | Endometrium | AEH | positive regulation of cell cycle process | 41/2100 | 236/18723 | 2.94e-03 | 2.09e-02 | 41 |
GO:00459317 | Endometrium | AEH | positive regulation of mitotic cell cycle | 23/2100 | 121/18723 | 7.76e-03 | 4.33e-02 | 23 |
GO:001049817 | Endometrium | EEC | proteasomal protein catabolic process | 112/2168 | 490/18723 | 6.99e-13 | 1.40e-10 | 112 |
GO:004316117 | Endometrium | EEC | proteasome-mediated ubiquitin-dependent protein catabolic process | 92/2168 | 412/18723 | 3.01e-10 | 3.23e-08 | 92 |
GO:004578713 | Endometrium | EEC | positive regulation of cell cycle | 59/2168 | 313/18723 | 1.04e-04 | 1.44e-03 | 59 |
GO:000020913 | Endometrium | EEC | protein polyubiquitination | 46/2168 | 236/18723 | 2.65e-04 | 3.04e-03 | 46 |
GO:003304413 | Endometrium | EEC | regulation of chromosome organization | 37/2168 | 187/18723 | 7.51e-04 | 7.05e-03 | 37 |
GO:004477213 | Endometrium | EEC | mitotic cell cycle phase transition | 71/2168 | 424/18723 | 8.68e-04 | 7.97e-03 | 71 |
GO:009006812 | Endometrium | EEC | positive regulation of cell cycle process | 44/2168 | 236/18723 | 9.39e-04 | 8.42e-03 | 44 |
GO:004593113 | Endometrium | EEC | positive regulation of mitotic cell cycle | 25/2168 | 121/18723 | 2.76e-03 | 1.97e-02 | 25 |
GO:19019893 | Endometrium | EEC | positive regulation of cell cycle phase transition | 23/2168 | 115/18723 | 6.04e-03 | 3.57e-02 | 23 |
GO:00073467 | Endometrium | EEC | regulation of mitotic cell cycle | 70/2168 | 457/18723 | 8.76e-03 | 4.74e-02 | 70 |
GO:0010498111 | Esophagus | ESCC | proteasomal protein catabolic process | 369/8552 | 490/18723 | 1.13e-41 | 1.80e-38 | 369 |
GO:0043161111 | Esophagus | ESCC | proteasome-mediated ubiquitin-dependent protein catabolic process | 312/8552 | 412/18723 | 3.53e-36 | 4.48e-33 | 312 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0412016 | Endometrium | AEH | Ubiquitin mediated proteolysis | 41/1197 | 142/8465 | 3.42e-06 | 4.27e-05 | 3.13e-05 | 41 |
hsa0516626 | Endometrium | AEH | Human T-cell leukemia virus 1 infection | 50/1197 | 222/8465 | 4.30e-04 | 3.11e-03 | 2.27e-03 | 50 |
hsa0412017 | Endometrium | AEH | Ubiquitin mediated proteolysis | 41/1197 | 142/8465 | 3.42e-06 | 4.27e-05 | 3.13e-05 | 41 |
hsa05166111 | Endometrium | AEH | Human T-cell leukemia virus 1 infection | 50/1197 | 222/8465 | 4.30e-04 | 3.11e-03 | 2.27e-03 | 50 |
hsa0516627 | Endometrium | EEC | Human T-cell leukemia virus 1 infection | 52/1237 | 222/8465 | 2.73e-04 | 2.36e-03 | 1.76e-03 | 52 |
hsa0516636 | Endometrium | EEC | Human T-cell leukemia virus 1 infection | 52/1237 | 222/8465 | 2.73e-04 | 2.36e-03 | 1.76e-03 | 52 |
hsa0412027 | Esophagus | ESCC | Ubiquitin mediated proteolysis | 122/4205 | 142/8465 | 6.53e-20 | 7.29e-18 | 3.74e-18 | 122 |
hsa0411023 | Esophagus | ESCC | Cell cycle | 126/4205 | 157/8465 | 1.34e-15 | 5.60e-14 | 2.87e-14 | 126 |
hsa05166211 | Esophagus | ESCC | Human T-cell leukemia virus 1 infection | 164/4205 | 222/8465 | 8.13e-14 | 2.09e-12 | 1.07e-12 | 164 |
hsa041146 | Esophagus | ESCC | Oocyte meiosis | 77/4205 | 131/8465 | 2.19e-02 | 4.80e-02 | 2.46e-02 | 77 |
hsa0412036 | Esophagus | ESCC | Ubiquitin mediated proteolysis | 122/4205 | 142/8465 | 6.53e-20 | 7.29e-18 | 3.74e-18 | 122 |
hsa0411033 | Esophagus | ESCC | Cell cycle | 126/4205 | 157/8465 | 1.34e-15 | 5.60e-14 | 2.87e-14 | 126 |
hsa05166310 | Esophagus | ESCC | Human T-cell leukemia virus 1 infection | 164/4205 | 222/8465 | 8.13e-14 | 2.09e-12 | 1.07e-12 | 164 |
hsa0411411 | Esophagus | ESCC | Oocyte meiosis | 77/4205 | 131/8465 | 2.19e-02 | 4.80e-02 | 2.46e-02 | 77 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ANAPC4 | SNV | Missense_Mutation | | c.1396N>G | p.Arg466Gly | p.R466G | Q9UJX5 | protein_coding | deleterious(0.03) | benign(0.182) | TCGA-5L-AAT1-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | letrozol | SD |
ANAPC4 | SNV | Missense_Mutation | novel | c.86N>G | p.Ser29Trp | p.S29W | Q9UJX5 | protein_coding | deleterious(0) | probably_damaging(0.986) | TCGA-A2-A3XZ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | CR |
ANAPC4 | SNV | Missense_Mutation | novel | c.500N>C | p.Leu167Pro | p.L167P | Q9UJX5 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-HN-A2NL-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD |
ANAPC4 | insertion | Frame_Shift_Ins | novel | c.2406_2407insAACCAACTCAGGAATGAAAAGGGGAT | p.Leu803AsnfsTer14 | p.L803Nfs*14 | Q9UJX5 | protein_coding | | | TCGA-AR-A0U0-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ANAPC4 | deletion | Frame_Shift_Del | | c.438delN | p.Asn148ThrfsTer67 | p.N148Tfs*67 | Q9UJX5 | protein_coding | | | TCGA-D8-A1XQ-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ANAPC4 | deletion | Frame_Shift_Del | novel | c.1044delN | p.Ile349Ter | p.I349* | Q9UJX5 | protein_coding | | | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
ANAPC4 | SNV | Missense_Mutation | | c.616N>T | p.Leu206Phe | p.L206F | Q9UJX5 | protein_coding | tolerated(0.32) | benign(0.03) | TCGA-C5-A901-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
ANAPC4 | SNV | Missense_Mutation | rs573056698 | c.1703G>A | p.Arg568His | p.R568H | Q9UJX5 | protein_coding | tolerated(0.17) | benign(0) | TCGA-MA-AA42-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD |
ANAPC4 | SNV | Missense_Mutation | | c.463N>C | p.Ile155Leu | p.I155L | Q9UJX5 | protein_coding | deleterious(0.03) | probably_damaging(0.952) | TCGA-AA-A00N-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
ANAPC4 | SNV | Missense_Mutation | novel | c.133N>G | p.Leu45Val | p.L45V | Q9UJX5 | protein_coding | tolerated(0.28) | probably_damaging(0.997) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR |